Determination of Dabigatran in Human Plasma Samples
Authors:
- 7 February 2012
- journal article
- research article
- Published by Georg Thieme Verlag KG in Seminars in Thrombosis and Hemostasis
- Vol. 38 (01) , 16-22
Abstract
The oral direct thrombin inhibitor dabigatran effectively prevents arterial and venous thromboembolism using fixed doses without the need for adjustment according to laboratory results. Dabigatran is eliminated from the circulation by ∼80% through the kidneys. However, the in vitro anticoagulant effect of dabigatran may be necessary to determine in special patient populations such as in the elderly, for renal impairment, before operations, bleeding or thrombotic episodes, and to monitor self-compliance. Several clotting and thrombin-specific chromogenic substrate assays are available to analyze the biological activity of dabigatran. All of them are prolonged in the presence of dabigatran. This article reports the effects of dabigatran on clinical routine assays and the potential usefulness for determination in special risk groups of patients when overdose or lack of compliance are suspected.Keywords
This publication has 14 references indexed in Scilit:
- Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non‐valvular atrial fibrillation from the RE‐LY trialJournal of Thrombosis and Haemostasis, 2011
- New oral antithrombotics: a need for laboratory monitoring. ForJournal of Thrombosis and Haemostasis, 2010
- Dabigatran versus Warfarin in Patients with Atrial FibrillationNew England Journal of Medicine, 2009
- Monitoring direct FXa-inhibitors and fondaparinux by Prothrombinase-induced Clotting Time (PiCT): Relation to FXa-activity and influence of assay modificationsThrombosis Research, 2008
- Determination of Antithrombin-Dependent Factor Xa Inhibitors by Prothrombin-Induced Clotting TimeSeminars in Thrombosis and Hemostasis, 2007
- Comparison of Two Different Ecarin Clotting Time MethodsJournal of Thrombosis and Thrombolysis, 2005
- The Use of Snake Venom-Derived Compounds for New Functional Diagnostic Test Kits in the Field of HaemostasisPathophysiology of Haemostasis and Thrombosis, 2005
- Effects of lepirudin, argatroban and melagatran and additional influence of phenprocoumon on ecarin clotting timeThrombosis Research, 2003
- Structure-Based Design of Novel Potent Nonpeptide Thrombin InhibitorsJournal of Medicinal Chemistry, 2002
- Effect of Phenprocoumon on Monitoring of Lepirudin, Argatroban, Melagatran and Unfractionated Heparin with the PiCT MethodPathophysiology of Haemostasis and Thrombosis, 2002